Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Valenti

Showing results (61-70 of 438) with videos related to

Pageof 44
Sort By:
Gastroenterology|March 4, 2003
Effect of iron depletion in patients with nonalcoholic fatty liver disease without carbohydrate intoleranceLuca Valenti, Anna Ludovica Fracanzani, Silvia Fargion
Journal of Hepatology|June 19, 2024
Estrogen receptor alpha in the female liver: Dr. Jekyll and Mr. HydeSara Della Torre, Alessandro Cherubini, Luca Valenti
Clinical Liver Disease|April 18, 2019
Role of iron in hepatocellular carcinomaSilvia Fargion, Luca Valenti, Anna Ludovica Fracanzani
Liver International : Official Journal of the International Association for the Study of the Liver|September 18, 2023
Usefulness of PNPLA3 variant for predicting hepatic events in steatotic liver disease: a matter of ethnicity or baseline risk?Umberto Vespasiani-Gentilucci, Luca Valenti, Stefano Romeo
Gastroenterology|June 27, 2021
Liver Field during Immunotherapy of Hepatocellular Carcinoma: Some Like It HotLuca Valenti, Mario U Mondelli, Massimo Colombo
Hepatology (Baltimore, Md.)|April 8, 2010
Hemochromatosis gene (HFE) mutations and cancer risk: expanding the clinical manifestations of hereditary iron overloadSilvia Fargion, Luca Valenti, Anna Ludovica Fracanzani
Journal of Hepatology|January 11, 2012
Interaction between IL28B and PNPLA3 genotypes in the pathogenesis of steatosis in chronic hepatitis C non genotype-3 patientsLuca Valenti, Alessio Aghemo, Albert Friedrich Stättermayer
Frontiers in Neurology|July 19, 2021
Clinical Determinants of Disease Progression in Patients With Beta-Sarcoglycan Gene MutationsGiulia Bruna Marchetti, Luca Valenti, Yvan Torrente
Current Pharmaceutical Design|February 12, 2013
Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatmentPaola Dongiovanni, Quentin M Anstee, Luca Valenti
Atherosclerosis|February 8, 2019
Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gapsRaul D Santos, Luca Valenti, Stefano Romeo
Pageof 44

Showing results (61-70 of 438) with videos related to

Sort By:
Pageof 44
Gastroenterology|March 4, 2003
Effect of iron depletion in patients with nonalcoholic fatty liver disease without carbohydrate intoleranceLuca Valenti, Anna Ludovica Fracanzani, Silvia Fargion
Journal of Hepatology|June 19, 2024
Estrogen receptor alpha in the female liver: Dr. Jekyll and Mr. HydeSara Della Torre, Alessandro Cherubini, Luca Valenti
Clinical Liver Disease|April 18, 2019
Role of iron in hepatocellular carcinomaSilvia Fargion, Luca Valenti, Anna Ludovica Fracanzani
Liver International : Official Journal of the International Association for the Study of the Liver|September 18, 2023
Usefulness of PNPLA3 variant for predicting hepatic events in steatotic liver disease: a matter of ethnicity or baseline risk?Umberto Vespasiani-Gentilucci, Luca Valenti, Stefano Romeo
Gastroenterology|June 27, 2021
Liver Field during Immunotherapy of Hepatocellular Carcinoma: Some Like It HotLuca Valenti, Mario U Mondelli, Massimo Colombo
Hepatology (Baltimore, Md.)|April 8, 2010
Hemochromatosis gene (HFE) mutations and cancer risk: expanding the clinical manifestations of hereditary iron overloadSilvia Fargion, Luca Valenti, Anna Ludovica Fracanzani
Journal of Hepatology|January 11, 2012
Interaction between IL28B and PNPLA3 genotypes in the pathogenesis of steatosis in chronic hepatitis C non genotype-3 patientsLuca Valenti, Alessio Aghemo, Albert Friedrich Stättermayer
Frontiers in Neurology|July 19, 2021
Clinical Determinants of Disease Progression in Patients With Beta-Sarcoglycan Gene MutationsGiulia Bruna Marchetti, Luca Valenti, Yvan Torrente
Current Pharmaceutical Design|February 12, 2013
Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatmentPaola Dongiovanni, Quentin M Anstee, Luca Valenti
Atherosclerosis|February 8, 2019
Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gapsRaul D Santos, Luca Valenti, Stefano Romeo
Pageof 44